- Dana-Farber scientists and colleagues report on a compound that can stop the blood cancer multiple myeloma from spreading, leading to a new approach in addressing metastasis, one of the deadliest aspects of cancer.
Tags: BasicResearch, MultipleMyeloma
- Researchers from the Susan F. Smith Center for Women’s Cancers at Dana-Farber report that for some women with recurrent ovarian cancer, a new drug combination has been found to stall the progression of the disease.
Tags: OvarianCancer, GynecologicCancers
- The American Society of Clinical Oncology (ASCO) today issued a new clinical practice guideline on chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer. The guideline provides detailed, evidenced-based information on the efficacy and side effects of various therapies.
- The Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO), has awarded Dana-Farber Cancer Institute a three-year certification for outpatient hematology-oncology practices that meet its highest standards for quality cancer care.
- The National Cancer Institute (NCI) has launched a new nationwide clinical trial to find out if two molecularly targeted drugs that have improved outcomes in advanced lung cancer can increase survival of patients with early-stage lung cancer that has been surgically removed.
Tags: LungCancer, TargetedTherapy
- Dana-Farber scientists and international colleagues have discovered how a single protein can exert both a push and a pull force to nudge a neuron in the desired direction, helping neurons navigate to their assigned places in the developing brain.
- A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, report scientists from Dana-Farber Cancer Institute.
- Children born with so-called “bubble boy” disease have the best chance of survival if they undergo a hematopoietic stem cell transplant as soon after birth as possible, according to a detailed analysis of 10 years published in the New England Journal of Medicine. The researchers say the findings argue for expanding newborn screening for the life-threatening immune disorder.
- Researchers find that targeting growth-driving cells within tumors, not the fastest-proliferating cells within tumors, may lead to more effective treatments.
- In a massive effort to catalog the molecular causes of stomach cancer, scientists, including researchers from Dana-Farber Cancer Institute, have identified four subtypes of tumors based on shared mutations and other molecular abnormalities.
Showing 11-20 of 533 items